Jeffery Aronin is the CEO of Paragon Biosciences, headquarted in Plymouth Meeting, Pennsylvania. Paragon Biosciences serves as a biotechnology incubator and investment company that helps to prolong the lives of those living with rare diseases by capitalizing on advanced innovative research of therapies and medication. Even though there have been some successes on groundbreaking discoveries for treating those already identified, Jeffery Aronin wants to stay ahead by taking it a step further. As a result,
Paragon Biosciences hires employees who are just as passionate as Jeffery Aronin in finding these advanced breakthroughs. Because of Jeffery Aronin’s talent for recruiting and keep a team with similar values to his own, many of his staff have been with the company for close to 20 years.
Jeffery Aronin has made it very clear that this is his life’s passion and doesn’t do it just for the sake of gaining the FDA’s approval. Paragon Biosciences is also an investment company because they provide financial assistance and resources for medical teams seeking such breakthroughs.
Jeffery Aronin is also dedicated to assisting those in underserved areas, such as rural areas. With Paragon Biosciences, all patients are recognized as their own individuals instead of as part of a statistic. Their staff members make an effort to become acquainted with patients and even hire those struggling with rare medical conditions themselves. Doctors also collaborate with researchers in order to ensure that the patients receive the best medical treatment for themselves.
On October 1, 2018, Jeffery Aronin and Paragon was recognized by Insights Care Magazine as one of the top 20 most influential leaders in healthcare. Over the years, Paragon has successfully made over 32 new drug approvals by R&D teams. The company has invested over $450 million in pharmaceutical compounds since October 2017. Many of their portfolio companies, including Castle Creek Pharma, Skyline Biosciences, and Emalex Biosciences are committed to helping find treatments that are overlooked by the larger pharmaceutical companies.